Clinical Trials
9 trialsNCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02693535 2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05405309 2025-06-03
CORONADO CLL
University of Utah
Phase 1/2 Terminated
NCT03233204 2024-12-11
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03205176 2021-05-06
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
Phase 1 Completed
NCT03575078 2019-09-25
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
University of Texas Southwestern Medical Center
Phase 1 Withdrawn